Drugs / Human Menopausal Gonadotropins
Trials 0
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04870502 Comparator | Apr 2019 → Jul 2020 | polycystic ovary syndrome | Saudi German Hospital - Madinah | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04157725 Comparator | Jun 2023 → Jan 2025 | infertility disorder, polycystic ovary syndrome | American University of Beirut Medical Center | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02979886 Background | Jan 2017 → Jun 2019 | female infertility | Miao benyu | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Menopausal Gonadotropins | “In group B, Human Menopausal Gonadotropins (hMG) (Merional® 75 I.U. vials, IBSA.) IM was given from 2nd day of the cycle” NCT04870502 ↗2“FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU” NCT04157725 ↗ |
| Known as | HMG | “FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU” NCT04157725 ↗1“Human Menopausal Gonadotropins (hMG)” NCT04870502 ↗ |
| Route | Intramuscular | “Human Menopausal Gonadotropins (hMG) (Merional® 75 I.U. vials, IBSA.) IM was given” NCT04870502 ↗ |